3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma

Oscar Otero-Marquez, Toco YP Chui, Alexander Pinhas, Maria V. Castanos Toral, Davis B. Zhou, Justin Migacz, Richard B. Rosen

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: To report the impact of intravitreal anti–vascular endothelial growth factor (VEGF) therapy on a retinal capillary hemangioma (RCH) using clinical OCT angiography (OCT-A) in addition to standard imaging modalities. Observations: A 25-year-old male patient with Von Hippel-Lindau (VHL) disease presented with a history of bilateral RCH. No view was present in the right eye. Examination of the left eye revealed six peripheral RCH, the smallest of which was temporal to the macula with active exudation. This RCH was thought to be the source of cystoid macular edema (CME) involving the fovea, and therefore, the source of vision decline. 11 injections of 1.25mg of Bevacizumab EA across 14-month was given. Comparison of the pre- and post-treatment OCT-A at the temporal RCH showed a reduction of CME and regression of RCH. Conclusion: Anti-VEGF therapy appeared to stabilize the visual acuity and produce partial regression of RCH. It offers a safe option when visual acuity is threatened. OCT and OCT-A have the ability to document the impact of antiangiogenic therapy on RCH. 3D renderings of OCT-A offer enhanced sensitivity to recognition of structural and functional changes of RCH which may prove useful for monitoring treatment response.

Original languageEnglish
Article number101394
JournalAmerican Journal of Ophthalmology Case Reports
StatePublished - Mar 2022


  • Anti-VEGF
  • Optical coherence tomography angiography
  • Retinal capillary hemangioma
  • Von Hippel-Lindau disease


Dive into the research topics of '3-D OCT angiographic evidence of Anti-VEGF therapeutic effects on retinal capillary hemangioma'. Together they form a unique fingerprint.

Cite this